{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:30:45Z","timestamp":1792643445022,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41433-018-0300-3","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T20:02:43Z","timestamp":1553889763000},"page":"1-21","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service"],"prefix":"10.1038","volume":"33","author":[{"given":"Richard P.","family":"Gale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Devonport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam H.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"El-Sherbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,29]]},"reference":[{"key":"300_CR1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"300_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"300_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"300_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"300_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","volume":"153","author":"SB Bloch","year":"2012","unstructured":"Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209\u201313.","journal-title":"Am J Ophthalmol"},{"key":"300_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ajo.2011.08.035","volume":"153","author":"A Skaat","year":"2012","unstructured":"Skaat A, Chetrit A, Belkin M, Kinori M, Kalter-Leibovici O. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2012;153:214\u201321.","journal-title":"Am J Ophthalmol"},{"key":"300_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/eye.2012.61","volume":"26","author":"E Rostron","year":"2012","unstructured":"Rostron E, McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? Eye (Lond). 2012;26:933\u20136.","journal-title":"Eye (Lond)"},{"key":"300_CR8","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/eye.2015.83","volume":"29","author":"S Borooah","year":"2015","unstructured":"Borooah S, Jeganathan VS, Ambrecht AM, Oladiwura D, Gavin M, Dhillon B, et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond). 2015;29:1156\u201361.","journal-title":"Eye (Lond)"},{"key":"300_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/eye.2015.288","volume":"30","author":"A Quartilho","year":"2016","unstructured":"Quartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye (Lond). 2016;30:602\u20137.","journal-title":"Eye (Lond)."},{"key":"300_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","volume":"96","author":"CG Owen","year":"2012","unstructured":"Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"300_CR11","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/eye.2011.343","volume":"26","author":"W Amoaku","year":"2012","unstructured":"Amoaku W, Blakeney S, Freeman M, Gale R, Johnston R, Kelly SP, et al. Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Eye (Lond). 2012;26Suppl 1:S2\u201321.","journal-title":"Eye (Lond)"},{"key":"300_CR12","unstructured":"National Institute for Health and Care Excellence. Age-related macular degeneration: diagnosis and management. NICE Guideline NG82. 2018. https:\/\/www.nice.org.uk\/guidance\/ng82 ."},{"key":"300_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/eye.2015.217","volume":"30","author":"V Chong","year":"2016","unstructured":"Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016;30:270\u201386.","journal-title":"Eye (Lond)"},{"key":"300_CR14","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"300_CR15","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897\u2013908.","journal-title":"N Engl J Med"},{"key":"300_CR16","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","volume":"36","author":"LN Kim","year":"2016","unstructured":"Kim LN, Mehta H, Barthelmes D, Nguyen V, Gillies MC. Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:1418\u201331.","journal-title":"Retina"},{"key":"300_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"300_CR18","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"Writing Committee for the UK\u00a0Age-Related Macular Degeneration\u00a0EMR Users Group.","year":"2014","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92\u2009976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014;121:1092\u2013101.","journal-title":"Ophthalmology"},{"key":"300_CR19","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"300_CR20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/eye.2017.67","volume":"31","author":"SR Rufai","year":"2017","unstructured":"Rufai SR, Almuhtaseb H, Paul RM, Stuart BL, Kendrick T, Lee H, et al. A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye (Lond). 2017;31:1337\u201344.","journal-title":"Eye (Lond)"},{"key":"300_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J; TREND Study Group. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125:57\u201365.","journal-title":"Ophthalmology"},{"key":"300_CR22","unstructured":"NHS Digital (Health and Social Care Information Centre). Hospital Outpatient Activity 2016-17. Published 28 November 2017."},{"key":"300_CR23","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00417-014-2885-y","volume":"253","author":"JP Real","year":"2015","unstructured":"Real JP, Granero GE, De Santis MO, Juarez CP, Palma SD, Kelly SP, et al. Rate of vision loss in neovascular age-related macular degeneration explored. Graefes Arch Clin Exp Ophthalmol. 2015;253:1859\u201365.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"300_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00417-010-1520-9","volume":"249","author":"PS Muether","year":"2011","unstructured":"Muether PS, Hermann MM, Koch K, Fauser S. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol. 2011;249:633\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"300_CR25","doi-asserted-by":"publisher","first-page":"e017771","DOI":"10.1136\/bmjopen-2017-017771","volume":"7","author":"PY Sim","year":"2017","unstructured":"Sim PY, Gajree S, Dhillon B, Borooah S. Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study. BMJ Open. 2017;7:e017771.","journal-title":"BMJ Open"},{"key":"300_CR26","first-page":"771","volume":"31","author":"B Foot","year":"2017","unstructured":"Foot B, MacEwen C. Surveillance of sight loss due to delay in ophthalmic treatment or review: frequency, cause and outcome. Eye (Lond). 2017;31:771\u20135.","journal-title":"Eye(Lond)"},{"key":"300_CR27","first-page":"422","volume":"31","author":"A Davis","year":"2017","unstructured":"Davis A, Baldwin A, Hingorani M, Dwyer A, Flanagan D. A review of 145 234 ophthalmic patient episodes lost to follow-up. Eye (Lond). 2017;31:422\u20139.","journal-title":"Eye(Lond)"},{"key":"300_CR28","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2147\/OPTH.S145732","volume":"11","author":"PJ Patel","year":"2017","unstructured":"Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957\u201366.","journal-title":"Clin Ophthalmol"},{"key":"300_CR29","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/eye.2017.86","volume":"31","author":"JS Talks","year":"2017","unstructured":"Talks JS, James P, Sivaprasad S, Johnston RL, McKibbin M, UK Aflibercept Users Group. Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration. Eye (Lond). 2017;31:1613\u201320.","journal-title":"Eye (Lond)"},{"key":"300_CR30","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/eye.2016.149","volume":"30","author":"G Liew","year":"2016","unstructured":"Liew G, Lee AY, Zarranz-Ventura J, Stratton I, Bunce C, Chakravarthy U, et al. The UK Neovascular AMD Database Report 3: inter-centre variation in VA outcomes and establishing real-world measures of care. Eye (Lond). 2016;30:1462\u20138.","journal-title":"Eye (Lond)"},{"key":"300_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2016.04.012","volume":"168","author":"IA Rodrigues","year":"2016","unstructured":"Rodrigues IA, Sprinkhuizen SM, Barthelmes D, Blumenkranz M, Cheung G, Haller J, et al. Defining a minimum set of standardized patient-centered outcome measures for macular degeneration. Am J Ophthalmol. 2016;168:1\u201312.","journal-title":"Am J Ophthalmol"},{"key":"300_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/eye.2012.225","volume":"27","author":"AH Ross","year":"2013","unstructured":"Ross AH, Donachie PH, Sallam A, Stratton IM, Mohamed Q, Scanlon PH, et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond). 2013;27:56\u201364.","journal-title":"Eye (Lond)"},{"key":"300_CR33","unstructured":"International Council of Ophthalmology. Number of ophthalmologists in practice and training worldwide. http:\/\/www.icoph.org\/ophthalmologists-worldwide.html ."},{"key":"300_CR34","unstructured":"The Royal College of Ophthalmologists. The Way Forward Age-Related Macular Degeneration and Diabetic Retinopathy Report. 2017. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2015\/10\/RCOphth-The-Way-Forward-AMD-300117.pdf ."},{"key":"300_CR35","unstructured":"Raguro A, Bisain L, Gencheva P, Chandran M, Laginaf M, Nair N, et al. Implementation and evaluation of a nurse-delivered intravitreal injection service. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2015 annual meeting; Denver, CO, 3\u20137 May 2015."},{"key":"300_CR36","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/eye.2014.69","volume":"28","author":"J DaCosta","year":"2014","unstructured":"DaCosta J, Hamilton R, Nago J, Mapani A, Kennedy E, Luckett T, et al. Implementation of a nurse-delivered intravitreal injection service. Eye (Lond). 2014;28:734\u201340.","journal-title":"Eye (Lond)"},{"key":"300_CR37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/eye.2014.234","volume":"29","author":"SP Mall","year":"2015","unstructured":"Mall SP, North L, Menon G, Moorman CM, Downes SM. Utilisation of orthoptists to give intravitreal injections-a multidisciplinary approach. Eye (Lond). 2015;29:290.","journal-title":"Eye (Lond)"},{"key":"300_CR38","unstructured":"Khan Y, Mapani A, Hamilton R, Rajendram R, Pavesio C. Incidence of endophthalmitis following intravitreal injection-real world outcomes from Moorfields Eye Hospital. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2016 annual meeting; Seattle, WA, 1\u20135 May 2016."},{"key":"300_CR39","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ophtha.2017.05.026","volume":"124","author":"S Rathi","year":"2017","unstructured":"Rathi S, Tsui E, Mehta N, Zahid S, Schuman JS. The current state of teleophthalmology in the United States. Ophthalmology. 2017;124:1729\u201334.","journal-title":"Ophthalmology"},{"key":"300_CR40","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2147\/OPTH.S26753","volume":"5","author":"SP Kelly","year":"2011","unstructured":"Kelly SP, Wallwork I, Haider D, Qureshi K. Teleophthalmology with optical coherence tomography imaging in community optometry. Evaluation of a quality improvement for macular patients. Clin Ophthalmol. 2011;5:1673\u20138.","journal-title":"Clin Ophthalmol"},{"key":"300_CR41","unstructured":"Rob N, North L, Ansari G, Zacharaki F, Chandran M, Menon G. Evaluation of the accuracy and efficiency of an optometrist led stable AMD clinic in a regional Age Related Macular Degeneration (AMD) Centre. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2013 annual meeting; Seattle, WA, 5\u20139 May 2013."},{"key":"300_CR42","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1111\/aos.12832","volume":"94","author":"KT Tsaousis","year":"2016","unstructured":"Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J. The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmol. 2016;94:e353\u20135.","journal-title":"Acta Ophthalmol"},{"key":"300_CR43","doi-asserted-by":"crossref","unstructured":"Kortuem K,\u00a0Fasler K,\u00a0Charnley A,\u00a0Khambati H,\u00a0Fasolo S,\u00a0Katz M, et al. Implementation of medical retina virtual clinics in a tertiary eye care referral centre. Br J Ophthalmol. 2018;102:1391\u20135.","DOI":"10.1136\/bjophthalmol-2017-311494"},{"key":"300_CR44","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/eye.2011.345","volume":"26","author":"M Mookhtiar","year":"2012","unstructured":"Mookhtiar M, Downey L. Combined OCT and colour fundus photography in virtual clinic assessments of wet AMD patients. Eye (Lond). 2012;26:619.","journal-title":"Eye (Lond)"},{"key":"300_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.puhe.2014.10.010","volume":"129","author":"AA Khan","year":"2015","unstructured":"Khan AA, Mustafa MZ, Sanders R. Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland). Public Health. 2015;129:117\u201323.","journal-title":"Public Health"},{"key":"300_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/opo.12312","volume":"36","author":"H Baker","year":"2016","unstructured":"Baker H, Ratnarajan G, Harper RA, Edgar DF, Lawrenson JG. Effectiveness of UK optometric enhanced eye care services: a realist review of the literature. Ophthalmic Physiol Opt. 2016;36:545\u201357.","journal-title":"Ophthalmic Physiol Opt"},{"key":"300_CR47","doi-asserted-by":"publisher","first-page":"e010685","DOI":"10.1136\/bmjopen-2015-010685","volume":"6","author":"BC Reeves","year":"2016","unstructured":"Reeves BC, Scott LJ, Taylor J, Harding SP, Peto T, Muldrew A, et al. Effectiveness of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial. BMJ Open. 2016;6:e010685.","journal-title":"BMJ Open"},{"key":"300_CR48","doi-asserted-by":"publisher","first-page":"e007400","DOI":"10.1136\/bmjopen-2014-007400","volume":"5","author":"D Townsend","year":"2015","unstructured":"Townsend D, Reeves BC, Taylor J, Chakravarthy U, O'Reilly D, Hogg RE, et al. Health professionals' and service users' perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trial. BMJ Open. 2015;5:e007400.","journal-title":"BMJ Open"},{"key":"300_CR49","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1136\/bjophthalmol-2015-308077","volume":"100","author":"KC Madhusudhana","year":"2016","unstructured":"Madhusudhana KC, Lee AY, Keane PA, Chakravarthy U, Johnston RL, Egan CA, et al. UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92\u2005976 intravitreal ranibizumab injections. Br J Ophthalmol. 2016;100:1617\u201322.","journal-title":"Br J Ophthalmol"},{"key":"300_CR50","unstructured":"National Institute for Health and Care Excellence. Into practice guide (PMG30). 2013 (updated 2015). https:\/\/www.nice.org.uk\/process\/pmg30 ."},{"key":"300_CR51","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","volume":"101","author":"S Yadav","year":"2017","unstructured":"Yadav S, Parry DG, Beare NAV, Pearce IA. Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians. Br J Ophthalmol. 2017;101:1377\u201380.","journal-title":"Br J Ophthalmol"},{"key":"300_CR52","unstructured":"The Royal College of Ophthalmologists. Age-related macular degeneration: guidelines for management. The Royal College of Ophthalmologists. 2013. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2014\/12\/2013-SCI-318-RCOphth-AMD-Guidelines-Sept-2013-FINAL-2.pdf ."},{"key":"300_CR53","unstructured":"Lucentis\u00ae (ranibizumab solution for injection) [summary of product characteristics]. Dublin, Ireland: Novartis Europharm Ltd; 2018. https:\/\/www.medicines.org.uk\/emc\/medicine\/19409 ."},{"key":"300_CR54","unstructured":"Eylea\u00ae (aflibercept solution for injection) [summary of product characteristics]. Leverkusen, Germany: Bayer AG; 2018. https:\/\/www.medicines.org.uk\/emc\/medicine\/27224 ."},{"key":"300_CR55","unstructured":"National Institute for Health and Care Excellence. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration\u00a0Technology appraisal guidance [TA155]. National Institute for Health and Care Excellence. 2008. https:\/\/www.nice.org.uk\/Guidance\/TA155 ."},{"key":"300_CR56","unstructured":"National Institute for Health and Care Excellence. Aflibercept solution for injection for treating wet age-related macular degeneration Technology appraisal guidance [TA294]. National Institute for Health and Care Excellence. 2013. https:\/\/www.nice.org.uk\/guidance\/ta294 ."},{"key":"300_CR57","unstructured":"Scottish Medicines Consortium. Aflibercept 40mg\/mL solution for intravitreal injection (Eylea\u00ae) SMC No. (857\/13). 2013. https:\/\/www.scottishmedicines.org.uk ."},{"key":"300_CR58","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","volume":"99","author":"AY Lee","year":"2015","unstructured":"Lee AY, Lee CS, Butt T, Xing W, Johnston RL, Chakravarthy U, et al. UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12. Br J Ophthalmol. 2015;99:1045\u201350.","journal-title":"Br J Ophthalmol"},{"key":"300_CR59","doi-asserted-by":"crossref","unstructured":"Butt T, Lee A, Lee C, Tufail A; UK AMD EMR Study Group. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes. BMJ Open. 2015;5:e006535.","DOI":"10.1136\/bmjopen-2014-006535"},{"key":"300_CR60","unstructured":"Koh AHC, Parikh S. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: 24-month results from the EVEREST II study. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting; Honolulu, HI, 29 April\u20133 May 2018."},{"key":"300_CR61","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/eye.2017.6","volume":"31","author":"H Almuhtaseb","year":"2017","unstructured":"Almuhtaseb H, Kanavati S, Rufai SR, Lotery AJ. One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration. Eye (Lond). 2017;31:878\u201383.","journal-title":"Eye (Lond)"},{"key":"300_CR62","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/bjophthalmol-2017-310939","volume":"102","author":"AY Lee","year":"2017","unstructured":"Lee AY, Butt T, Chew E, Agron E, Clemons TE, Egan CA, et al. Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data. Br J Ophthalmol. 2017;102:465\u201372.","journal-title":"Br J Ophthalmol"},{"key":"300_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ajo.2017.03.005","volume":"177","author":"H Senra","year":"2017","unstructured":"Senra H, Balaskas K, Mahmoodi N, Aslam T. Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration. Am J Ophthalmol. 2017;177:213\u201324.","journal-title":"Am J Ophthalmol"},{"key":"300_CR64","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721\u201331.","journal-title":"Eye (Lond)"},{"key":"300_CR65","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.survophthal.2018.02.004","volume":"63","author":"I Mantel","year":"2018","unstructured":"Mantel I, Gillies MC, Souied EH. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration (nAMD). Surv Ophthalmol. 2018;63:638\u201345.","journal-title":"Surv Ophthalmol"},{"key":"300_CR66","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/OPTH.S125676","volume":"11","author":"K Spooner","year":"2017","unstructured":"Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clin Ophthalmol. 2017;11:161\u201377.","journal-title":"Clin Ophthalmol"},{"key":"300_CR67","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/IAE.0000000000000751","volume":"36","author":"V Sarao","year":"2016","unstructured":"Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P. Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. 2016;36:770\u20137.","journal-title":"Retina"},{"key":"300_CR68","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1136\/bjophthalmol-2015-308090","volume":"100","author":"D Barthelmes","year":"2016","unstructured":"Barthelmes D, Campain A, Nguyen P, Arnold JJ, McAllister IL, Simpson JM, et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016;100:1640\u20135.","journal-title":"Br J Ophthalmol"},{"key":"300_CR69","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/IAE.0000000000001637","volume":"38","author":"CS Lee","year":"2017","unstructured":"Lee CS, Kim AJ, Baughman D, Egan C, Bailey C, Johnston RL, et al. Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina. 2017;38:951\u20136.","journal-title":"Retina"},{"key":"300_CR70","doi-asserted-by":"crossref","unstructured":"Seguin-Greenstein S,\u00a0Lightman\u00a0S,\u00a0Tomkins-Netzer O. A meta-analysis of studies evaluating visual and anatomical outcomes in patients with\u00a0treatment-resistant neovascular age-related macular degeneration following\u00a0switching\u00a0to\u00a0treatment\u00a0with\u00a0aflibercept. J Ophthalmol. 2016;2016:4095852.","DOI":"10.1155\/2016\/4095852"},{"key":"300_CR71","doi-asserted-by":"publisher","unstructured":"Ferris\u00a0FL 3rd,\u00a0Maguire MG,\u00a0Glassman AR,\u00a0Ying GS,\u00a0Martin DF. Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related\u00a0macular degeneration\u00a0and diabetic\u00a0macular\u00a0edema. JAMA Ophthalmol. 2016. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.4820 . 22 Dec 2016 [Epub ahead of print]","DOI":"10.1001\/jamaophthalmol.2016.4820"},{"key":"300_CR72","unstructured":"Framme C, Kodjikian L. Regularity of treatment in nAMD: 12-month results of the PERSEUS and RAINBOW studies. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2017 annual meeting; Baltimore,\u00a0MD, 7\u201311 May 2017."},{"key":"300_CR73","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/eye.2014.64","volume":"28","author":"C Ehlken","year":"2014","unstructured":"Ehlken C, Jungmann S, B\u00f6hringer D, Agostini HT, Junker B, Pielen A. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond). 2014;28:538\u201345.","journal-title":"Eye (Lond)"},{"key":"300_CR74","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/OPTH.S160367","volume":"12","author":"A Dirani","year":"2018","unstructured":"Dirani A, Mantel I. Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. Clin Ophthalmol. 2018;12:593\u2013600.","journal-title":"Clin Ophthalmol"},{"key":"300_CR75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000451065","volume":"236","author":"R Gale","year":"2016","unstructured":"Gale R, Korobelnik JF, Yang Y, Wong TY. Characteristics and predictors of early and delayed responders to ranibizumab treatment in neovascular age-related macular degeneration: a retrospective analysis from the ANCHOR, MARINA, HARBOR, and CATT trials. Ophthalmologica. 2016;236:193\u2013200.","journal-title":"Ophthalmologica"},{"key":"300_CR76","doi-asserted-by":"publisher","first-page":"e697","DOI":"10.1111\/aos.12417","volume":"92","author":"A Vaze","year":"2014","unstructured":"Vaze A, Fraser-Bell S, Gillies M. Consequences of long-term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age-related macular degeneration. Acta Ophthalmol. 2014;92:e697\u20138.","journal-title":"Acta Ophthalmol"},{"key":"300_CR77","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2016.07.012","volume":"123","author":"RW Essex","year":"2016","unstructured":"Essex RW, Nguyen V, Walton R, Arnold JJ, McAllister IL, Guymer RH, et al. Treatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degeneration. Ophthalmology. 2016;123:2393\u20132400.","journal-title":"Ophthalmology"},{"key":"300_CR78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","volume":"65","author":"H Mehta","year":"2018","unstructured":"Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, et al. Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res. 2018;65:127\u201346.","journal-title":"Prog Retin Eye Res"},{"key":"300_CR79","unstructured":"The College of Optometrists. Guidance for Professional Practice. 2017. http:\/\/guidance.college-optometrists.org\/guidance-contents\/knowledge-skills-and-performance-domain\/the-routine-eye-examination\/#open:68 ."},{"key":"300_CR80","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","volume":"121","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology. 2014;121:1966\u201375.","journal-title":"Ophthalmology"},{"key":"300_CR81","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000329473","volume":"226","author":"R Silva","year":"2011","unstructured":"Silva R, Cachulo ML, Fonseca P, Bernardes R, Nunes S, Vilhena N, et al. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Ophthalmologica. 2011;226:110\u20138.","journal-title":"Ophthalmologica"},{"key":"300_CR82","unstructured":"Chopra R, Wagner SK, Fasler K, Kortue KU, Pontiko N, Afshar F, et al. Development of neovascular age-related macular degeneration in fellow eyes of patients undergoing intravitreal anti-VEGF therapy at a large tertiary ophthalmic hospital. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting; Honolulu, HI, 29 April\u20133 May 2018."},{"key":"300_CR83","unstructured":"Burton BJ, Webber TH, Tufail A, Lee AY. Treat-and-extend follow-up regimens for neovascular age-related macular degeneration adversely affect VA in the second eye which is usually the better seeing eye. Poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2017 annual meeting; Baltimore, MD, 5\u201311 May 2017."},{"key":"300_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000469652","volume":"238","author":"JK Chew","year":"2017","unstructured":"Chew JK, Zhu M, Broadhead GK, Luo K, Hong T, Chang AA. Bilateral neovascular age-related macular degeneration: comparisons between first and second eyes. Ophthalmologica. 2017;238:23\u201330.","journal-title":"Ophthalmologica"},{"key":"300_CR85","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00417-014-2839-4","volume":"253","author":"M McKibbin","year":"2015","unstructured":"McKibbin M, Baker L, Baxter P, Czoski-Muray C, Setty R. The accuracy of home monitoring to detect disease activity during maintenance therapy for neovascular ARMD. Graefes Arch Clin Exp Ophthalmol. 2015;253:1479\u201383.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"300_CR86","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/eye.2014.104","volume":"28","author":"L Faes","year":"2014","unstructured":"Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond). 2014;28:788\u201396.","journal-title":"Eye (Lond)"},{"key":"300_CR87","unstructured":"The MONARCH study protocol. 2017. https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2011820 ."},{"key":"300_CR88","unstructured":"EDNA: Early Detection of Neovascular Age-related macular degeneration protocol. 2015. https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2007200 ."},{"key":"300_CR89","unstructured":"The Royal College of Ophthalmologists. Ophthalmic Service Guidance: Intravitreal injection therapy. The Royal College of Ophthalmologists. 2018. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2018\/02\/Intravitreal-Injection-Therapy-August-2018-2.pdf ."},{"key":"300_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0010-y","volume":"1","author":"R Merani","year":"2015","unstructured":"Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retin Vitr. 2015;1:9. eCollection 2015.","journal-title":"Int J Retin Vitr"},{"key":"300_CR91","doi-asserted-by":"crossref","unstructured":"Hunyor AP,\u00a0Merani R,\u00a0Darbar A,\u00a0Korobelnik\u00a0JF,\u00a0Lanzetta P,\u00a0Okada AA. Topical\u00a0antibiotics\u00a0and intravitreal injections. Acta Ophthalmol. 2018;96:435\u201341.","DOI":"10.1111\/aos.13417"},{"key":"300_CR92","unstructured":"The Vision Academy. Bilateral anti-VEGF treatment. Vision Academy Viewpoint. 2017. https:\/\/www.visionacademy.org\/sites\/g\/files\/dvfzv331\/files\/2018-05\/vision-academy-viewpoint-bilateral-anti-vegf.pdf ."},{"key":"300_CR93","unstructured":"Hamilton RD, Tasiopoulou A, Mapani A, Vasilopoulos P, Preston G. Recurrence of choroidal neovascularization after cataract operation in age related macular degeneration. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 annual meeting; Honolulu, HI, 29 April\u20133 May 2018."},{"key":"300_CR94","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/IAE.0000000000000520","volume":"35","author":"VS Dedania","year":"2015","unstructured":"Dedania VS, Bakri SJ. Sustained elevation of intraocular pressure after intravitreal anti-VEGF agents: what is the evidence? Retina. 2015;35:841\u201358.","journal-title":"Retina"},{"key":"300_CR95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","volume":"133","author":"SB Bressler","year":"2015","unstructured":"Bressler SB, Almukhtar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, et al. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol. 2015;133:589\u201397.","journal-title":"JAMA Ophthalmol"},{"key":"300_CR96","unstructured":"Rashid A, Quhill F, Narendren N, Pushpoth S, Yang YC. Effect of iopidine administration prior to intravitreal Lucentis injection on intraocular pressure spike. Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2009 annual meeting; Fort Lauderdale, FL, 3\u20137 May 2009."},{"key":"300_CR97","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/eye.2014.180","volume":"28","author":"CD Murray","year":"2014","unstructured":"Murray CD, Wood D, Allgar V, Walters G, Gale RP. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond). 2014;28:1218\u201322.","journal-title":"Eye (Lond)"},{"key":"300_CR98","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/eye.2016.227","volume":"31","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Klimscha S, Waldstein SM, Bogunovi\u0107 H. A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration. Eye (Lond). 2017;31:26\u201344.","journal-title":"Eye (Lond)"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0300-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0300-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:02Z","timestamp":1684616762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-018-0300-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":98,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1038\/s41433-018-0300-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"29 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors except NJ received honoraria from Bayer plc. RPG: consulting fees from Bayer and Novartis; lecture fees from Bayer and Novartis; research funding from Bayer and Novartis. SM: consulting fees from Bayer and Novartis; lecture fees from Bayer and Novartis; grant support (travel) from Bayer, Novartis and Allergan. HD: consulting fees from Bayer; lecture fees from Bayer. PJP: consulting fees from Bayer and Novartis; lecture fees from Bayer; research funding from Bayer. AHR: consulting fees from Bayer, Allergan and AbbVie; lecture fees from Bayer. GW: consulting fees from Bayer; lecture fees from Bayer. LD: consulting fees from Bayer, Novartis and Alimera Sciences; lecture fees\u00a0from Bayer, Novartis and Heidelberg Engineering. SE-S: consulting fees from Bayer, Novartis and Alimera Sciences; Novartis and Alimera Sciences. MF: consulting fees from Bayer; lecture fees from Novartis. SB: consulting fees from Bayer. NJ: owns Bayer shares and is employed by Bayer plc, serving as Senior Medical Advisor, Specialty Medicine\u2013Ophthalmology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}